Insights

Platform Integration Recursion completed its combination with Exscientia in November 2024, creating a vertically integrated, technology enabled drug discovery platform. This integration may create demand for solutions that unify workflows, data, research systems, and collaboration across the combined organization.

AI Research The company’s focus on AI driven drug discovery, including precision designed LSD1 and MALT1 inhibitors, makes advanced computing, data management, model development, and research infrastructure relevant areas for business development outreach.

Partner Milestones Exscientia advanced two Sanofi collaboration programs into lead optimization and received $15 million in milestone payments. This progress suggests active partner programs where scalable research operations, program tracking, and collaboration tools may be valuable.

Growth Opportunities The merger and ongoing drug programs may increase operational complexity and needs across teams. Potential sales conversations could focus on integration support, secure collaboration, workflow automation, and tools that help researchers and business teams work across organizational boundaries.

Competitive Position Recursion now combines Exscientia’s capabilities with its own position in the AI drug discovery market, competing with firms such as BenevolentAI, Insilico Medicine, and Atomwise. Solutions that improve research productivity, security, or speed to development could support differentiation, though current revenue and employee figures in the data may not reflect the combined company.

Similar companies to Exscientia

Exscientia Tech Stack

Exscientia uses 8 technology products and services including Docker, Google Workspace, Claude by Anthropic, and more. Explore Exscientia's tech stack below.

Media & News

Exscientia's Email Address Formats

Exscientia uses at least 10 email formats:
Exscientia Email FormatsExamplePercentage
FLast@exscientia.co.ukJDoe@exscientia.co.uk
96%
F.Last@exscientia.co.ukJ.Doe@exscientia.co.uk
3%
First@exscientia.co.ukJohn@exscientia.co.uk
1%
FLast@exscientia.aiJDoe@exscientia.ai
94%
Last@exscientia.aiDoe@exscientia.ai
4%
F.Last@exscientia.aiJ.Doe@exscientia.ai
1%
First.Last@exscientia.aiJohn.Doe@exscientia.ai
1%
First.Last@recursion.comJohn.Doe@recursion.com
85%
Last@recursion.comDoe@recursion.com
14%
First@recursion.comJohn@recursion.com
1%

Frequently Asked Questions

What is Exscientia's stock symbol?

Minus sign iconPlus sign icon
Exscientia is a publicly traded company; the company's stock symbol is EXAI.

What is Exscientia's official website and social media links?

Minus sign iconPlus sign icon
Exscientia's official website is recursion.com and has social profiles on LinkedIn and Crunchbase.

How much revenue does Exscientia generate?

Minus sign iconPlus sign icon
As of October 2026, Exscientia's annual revenue is estimated to be $1M - $10M.

What is Exscientia's SIC code and NAICS code?

Minus sign iconPlus sign icon
Exscientia's SIC code is 8731 - Commercial Physical and Biological Research and NAICS code is 541714 - Research and Development in Biotechnology (except Nanobiotechnology).

How many employees does Exscientia have currently?

Minus sign iconPlus sign icon
As of October 2026, Exscientia has approximately 42 employees across 5 continents, including Europe, Asia and North America. Key team members include Chief People Officer: C. R., Chief Information Officer: E. J. and Associate Director, Chief Revenue Officer Management: C. P. Explore Exscientia's employee directory with LeadIQ.

What industry does Exscientia belong to?

Minus sign iconPlus sign icon
Exscientia operates in the Biotechnology Research industry.

What technology does Exscientia use?

Minus sign iconPlus sign icon
Exscientia's tech stack includes Docker, Google Workspace, Claude by Anthropic, Atlassian Jira, DocuSign, Cisco, Palo Alto Firewalls and Webflow.

What is Exscientia's email format?

Minus sign iconPlus sign icon
Exscientia's email format typically follows the pattern of FLast@exscientia.co.uk. Find more Exscientia email formats with LeadIQ.

How much funding has Exscientia raised to date?

Minus sign iconPlus sign icon
As of October 2026, Exscientia has raised $377M in funding. The last funding round occurred on Dec 05, 2023 for $2.3M.

When was Exscientia founded?

Minus sign iconPlus sign icon
Exscientia was founded in 2013.
Exscientia logo

Exscientia

Biotechnology ResearchEngland, United Kingdom11-50 Employees

Exscientia is a biotechnology research company based in Oxford, England, focused on AI-driven drug discovery and development. In October 2024 it reported progress in a collaboration with Sanofi, advancing two discovery programmes toward lead optimisation. In November 2024 the business combination with Recursion was completed, making Exscientia a wholly owned subsidiary of Recursion. The merger is described as creating a vertically integrated, technology-enabled drug discovery platform. The arrangement places Exscientia within Recursion's ecosystem, aligning its capabilities with an AI-driven approach to drug discovery. The company is based in Oxford, England, situating it within the United Kingdom's biotechnology research landscape.

Section iconCompany Overview

SIC Code
8731 - Commercial Physical and Biological Research
Stock Symbol
EXAI
NAICS Code
541714 - Research and Development in Biotechnology (except Nanobiotechnology)
Founded
2013
Employees
11-50

Section iconFunding & Financials

  • $377M

    Exscientia has raised a total of $377M of funding over 9 rounds. Their latest funding round was raised on Dec 05, 2023 in the amount of $2.3M as a Grant.

  • $1M - $10M

    Exscientia's revenue is estimated to be in the range of $1M - $10M

Ready to create more pipeline?

Get a demo and discover why thousands of SDR and Sales teams trust
LeadIQ to help them build pipeline confidently.

© LeadIQ, Inc. All rights reserved.